These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20842339)

  • 1. [Molecular principles of tau-induced toxicity: new experimental therapy strategies for treatment of Alzheimer's disease].
    Schneider A; Falkai P; Papassotiropoulos A
    Nervenarzt; 2010 Nov; 81(11):1289-90, 1292, 1294, passim. PubMed ID: 20842339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
    Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
    Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatments for Alzheimer's disease emerge.
    Selkoe DJ
    Science; 2021 Aug; 373(6555):624-626. PubMed ID: 34353940
    [No Abstract]   [Full Text] [Related]  

  • 4. [Alzheimer's disease: cellular and molecular aspects].
    Octave JN; Pierrot N
    Bull Acad Natl Med; 2008 Feb; 192(2):323-31; discussion 331-2. PubMed ID: 18819686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pulse of drug development for Alzheimer's disease.
    Rafii MS
    Rev Recent Clin Trials; 2010 Jan; 5(1):57-62. PubMed ID: 20205688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs: a tangled web of targets.
    Gravitz L
    Nature; 2011 Jul; 475(7355):S9-11. PubMed ID: 21760583
    [No Abstract]   [Full Text] [Related]  

  • 7. Alzheimer's disease: Mental plaque removal.
    De Strooper B; Woodgett J
    Nature; 2003 May; 423(6938):392-3. PubMed ID: 12761533
    [No Abstract]   [Full Text] [Related]  

  • 8. Pathophysiological mechanism and natural preventive and therapeutic strategies of Alzheimer's disease.
    Basli A; Bounaas J
    Nutr Health; 2023 Sep; 29(3):403-413. PubMed ID: 36377316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
    Avila J; Wandosell F; Hernández F
    Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BACE1 RNA interference improves spatial memory and attenuates Aβ burden in a streptozotocin-induced tau hyperphosphorylated rat model.
    Yu CJ; Liu W; Chen HY; Wang L; Zhang ZR
    Cell Biochem Funct; 2014 Oct; 32(7):590-6. PubMed ID: 25230339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
    Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
    J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
    Suzuki K; Iwata A; Iwatsubo T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic strategy by manipulating some protease activities for Alzheimer's disease].
    Iwata N; Higuchi M; Saido TC
    Nihon Yakurigaku Zasshi; 2008 May; 131(5):320-5. PubMed ID: 18480559
    [No Abstract]   [Full Text] [Related]  

  • 16. Spatiotemporal activation of the C/EBPβ/δ-secretase axis regulates the pathogenesis of Alzheimer's disease.
    Wang H; Liu X; Chen S; Ye K
    Proc Natl Acad Sci U S A; 2018 Dec; 115(52):E12427-E12434. PubMed ID: 30530690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacology of amyloid precursor protein processing.
    Racchi M; Govoni S
    Exp Gerontol; 2003; 38(1-2):145-57. PubMed ID: 12543272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau aggregation and its interplay with amyloid-β.
    Nisbet RM; Polanco JC; Ittner LM; Götz J
    Acta Neuropathol; 2015 Feb; 129(2):207-20. PubMed ID: 25492702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau therapeutic strategies for the treatment of Alzheimer's disease.
    Churcher I
    Curr Top Med Chem; 2006; 6(6):579-95. PubMed ID: 16712493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein aggregation in Alzheimer's disease: Aβ and τ and their potential roles in the pathogenesis of AD.
    Thal DR; Fändrich M
    Acta Neuropathol; 2015 Feb; 129(2):163-5. PubMed ID: 25600324
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.